- Home
- SKHY vs LLY Comparison
SKHY vs LLY Comparison
Compare SKHY & LLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKHY | LLY |
|---|---|---|
| Founded | N/A | 1876 |
| Country | South Korea | United States |
| Employees | 33625 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1T | 979.6B |
| IPO Year | 2026 | 2007 |
Fundamental Metrics
Financial Performance| Metric | SKHY | LLY |
|---|---|---|
| Price | $154.47 | $1,192.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 19 |
| Target Price | N/A | ★ $1,218.84 |
| AVG Volume (30 Days) | ★ 28.5M | 2.1M |
| Earning Date | N/A | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.81% |
| EPS Growth | N/A | ★ 95.99 |
| EPS | N/A | ★ 8.26 |
| Revenue | N/A | ★ $65,179,000,000.00 |
| Revenue This Year | N/A | $27.15 |
| Revenue Next Year | N/A | $16.04 |
| P/E Ratio | ★ N/A | $143.50 |
| Revenue Growth | N/A | ★ 44.70 |
| 52 Week Low | $151.10 | $623.78 |
| 52 Week High | $177.93 | $1,249.45 |
Technical Indicators
Market Signals| Indicator | SKHY | LLY |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 56.56 |
| Support Level | N/A | $1,032.70 |
| Resistance Level | N/A | $1,249.45 |
| Average True Range (ATR) | 0.00 | 33.25 |
| MACD | 0.00 | -5.03 |
| Stochastic Oscillator | 0.00 | 50.76 |
Price Performance
Historical ComparisonAbout SKHY SK hynix Inc. American Depositary Shares
SK hynix is a semiconductor memory manufacturer with around 60%-70% of its revenue from DRAM and 30%-35% of its revenue from NAND. The company is both the second-largest DRAM and NAND supplier globally with a 33% and 21% market share, respectively, as of 2024. SK Hynix increased its market position in NAND from fourth to second, after acquiring Intel's NAND business in 2021. SK Square, an investment management company spun off from SK Telecom, is SK Hynix's largest shareholder and currently holds 20% of the company's shares.
About LLY Eli Lilly and Company
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.